[1]卜 烨,张晨洁.生存素、人类表皮生长因子受体2、巨囊性病液体蛋白15、 Yes相关蛋白表达对乳腺癌患者术后复发转移的预测价值[J].陕西医学杂志,2025,54(1):127-131.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.026]
　BU Ye,ZHANG Chenjie.The predictive value of Survivin,HER-2,GCDFP15 and YAP protein expression in postoperative recurrence and metastasis of breast cancer patients[J].,2025,54(1):127-131.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.026]
点击复制

生存素、人类表皮生长因子受体2、巨囊性病液体蛋白15、 Yes相关蛋白表达对乳腺癌患者术后复发转移的预测价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年1期
页码:
127-131
栏目:
临床病理
出版日期:
2025-01-05

文章信息/Info

Title:
The predictive value of Survivin,HER-2,GCDFP15 and YAP protein expression in postoperative recurrence and metastasis of breast cancer patients
作者:
卜 烨1; 张晨洁2
(1.保定市第二中心医院普外科,河北 保定 072750; 2.保定市第二中心医院肾内科,河北 保定 072750)
Author(s):
BU Ye; ZHANG Chenjie
(Department of General Surgery,Baoding Second Central Hospital,Baoding 072750,China)
关键词:
乳腺癌;  生存素;  人类表皮生长因子受体2;  巨囊性病液体蛋白15;  Yes相关蛋白;  复发;  转移;  预测价值
Keywords:
Breast cancer;  Survivin;  Human epidermal growth factor receptor 2;  Gross cystic disease fluid protein;  Yes related protein;  Recurrence;  Transfer;  Predicted value
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2025.01.026
文献标志码:
A
摘要:
目的:研究生存素(Survivin)、人类表皮生长因子受体2(HER-2)、巨囊性病液体蛋白15(GCDFP15)、Yes相关蛋白(YAP)表达对乳腺癌患者术后复发转移的预测价值。方法:收集156例经乳腺癌改良根治术治疗的乳腺癌患者乳腺癌病理组织及癌旁正常组织,比较乳腺癌患者癌组织和癌旁正常组织Survivin、HER-2、GCDFP15、YAP蛋白表达情况; 所有患者术后均随访2年,根据患者术后随访期间复发转移情况将其分为Ⅰ组(51例)和Ⅱ组(105例),统计两组一般资料,比较两组癌组织Survivin、HER-2、GCDFP15、YAP蛋白表达情况,分析乳腺癌患者术后2年内复发转移的影响因素及癌组织Survivin、HER-2、GCDFP15、YAP蛋白单一及联合检测对乳腺癌患者术后2年复发转移的预测价值。结果:癌组织Survivin、HER-2、GCDFP15阳性表达率高于正常组织,YAP阳性表达率低于正常组织(均P<0.05)。Ⅰ组低分化、临床分期Ⅲ期患者占比高于Ⅱ组(均P<0.05)。Ⅰ 组癌组织Survivin、HER-2、GCDFP15阳性表达率高于Ⅱ组,YAP阳性表达率低于Ⅱ组(均P<0.05)。分化程度为低分化、临床分期Ⅲ期及Survivin、HER-2、GCDFP15蛋白阳性表达均为乳腺癌患者术后2年内复发转移的独立危险因素(OR=2.092、1.992、2.059、1.815、1.857,均P<0.05); YAP蛋白阳性表达为乳腺癌患者术后2年内复发转移的保护因素(OR=0.489,P<0.05)。癌组织Survivin、HER-2、GCDFP15、YAP蛋白联合预测乳腺癌患者术后2年复发转移的曲线下面积(AUC)值高于四者单独检测(均P<0.05)。结论:乳腺癌的发生与Survivin、HER-2、GCDFP15、YAP蛋白表达情况有关,且患者术后2年复发转移的发生与其分化程度、临床分期及Survivin、HER-2、GCDFP15、YAP蛋白表达情况有关,同时Survivin、HER-2、GCDFP15、YAP蛋白联合可有效提高对乳腺癌患者术后2年复发转移的预测价值。
Abstract:
Objective:To study the predictive value of Survivin,human epidermal growth factor receptor 2(HER-2),giant cystic disease fluid protein 15(GCDFP15)and Yes-associated protein(YAP)expression in postoperative recurrence and metastasis of breast cancer patients.Methods:The pathological tissues and normal tissues adjacent to breast carcinoma of breast cancer in 156 patients with breast cancer treated by modified radical mastectomy were collected.The expression of Survivin,HER-2,GCDFP15 and YAP protein in cancer tissues and normal tissues adjacent to breast carcinoma of breast cancer patients were compared.All patients were followed up for 2 years after operation.According to the recurrence and metastasis of patients during the follow-up period,they were divided into the Ⅰ group(51 cases)and the Ⅱ group(105 cases).The general data of the two groups were statistically analyzed.The expression of Survivin,HER-2,GCDFP15 and YAP protein in cancer tissues of the two groups was compared.The influencing factors of recurrence and metastasis of breast cancer patients within 2 years after operation and the predictive value of single and combined detection of Survivin,HER-2,GCDFP15 and YAP protein in cancer tissues for recurrence and metastasis of breast cancer patients within 2 years after operation were analyzed.Results:The positive expression rates of Survivin,HER-2 and GCDFP15 protein in cancer tissues were higher than those in normal tissues,and the positive expression rate of YAP protein was lower than that in normal tissues(all P<0.05).The proportion of patients with poor differentiation and clinical stage Ⅲ in the Ⅰ group was higher than that in the Ⅱ group(all P<0.05).The positive expression rates of Survivin,HER-2 and GCDFP15 protein in cancer tissues of the Ⅰ group were higher than those in the Ⅱ group,and the positive expression rate of YAP protein was lower than that in Ⅱ group(all P<0.05).Poor differentiation,clinical stage Ⅲ and positive expression of Survivin,HER-2 and GCDFP15 protein were independent risk factors for recurrence and metastasis of breast cancer patients within 2 years after operation(OR=2.092,1.992,2.059,1.815,1.857,all P<0.05).The positive expression of YAP protein was a protective factor for recurrence and metastasis of breast cancer patients within 2 years after operation(OR=0.489,P<0.05).The area under the curve(AUC)value of Survivin,HER-2,GCDFP15 and YAP protein combined in predicting recurrence and metastasis of breast cancer patients 2 years after operation was higher than that of the four alone(all P<0.05).Conclusion:The occurrence of breast cancer was related to the expression of Survivin,HER-2,GCDFP15 and YAP protein,and the occurrence of recurrence and metastasis 2 years after operation was related to the degree of differentiation,clinical stage and the expression of Survivin,HER-2,GCDFP15 and YAP protein.At the same time,the combination of Survivin,HER-2,GCDFP15 and YAP protein could effectively improve the predictive value of recurrence and metastasis 2 years after operation in breast cancer patients.

参考文献/References:

[1] BURSTEIN H J,CURIGLIANO G,THURLIMANN B,et al.Customizing local and systemic therapies for women with early breast cancer:The St.gallen international consensus guidelines for treatment of early breast cancer 2021[J].Ann Oncol,2021,32(10):1216-1235.
[2] 骆小珊,谢甦,朱曼荆,等.薯蓣丸联合紫杉醇抑制三阴性乳腺癌细胞MDA-MB-231上皮间质转化作用和机制研究[J].陕西中医,2023,44(9):1163-1168.
[3] ZHANG H,MENG Y,JIANG R,et al.Effect of multimodal exercise on cancer-related fatigue in patients undergoing simultaneous radiotherapy and chemotherapy:A randomized trial in patients with breast cancer[J].Altern Ther Health Med,2023,29(5):233-237.
[4] 张蕾,赵婵,王海蕊,等.乳腺癌手术切除患者放疗前后外周血单个核细胞中Survivin、OTUD3 mRNA变化及与预后的关系[J].实用癌症杂志,2023,38(5):766-770.
[5] 纵然,杨丽萍,束宏敏,等.HER-2阳性浸润性乳腺癌患者MRI影像多参数特征分析[J].中国CT和MRI杂志,2023,21(6):81-82.
[6] 郁玉文,范晓芳.GCDFP-15、ER、PR、C-erbB-2、Her2/Neu表达与乳腺癌超声征象的关系[J].北华大学学报(自然科学版),2021,22(1):75-78.
[7] 李冬梅,孟维合,康聪.他克莫司调节YAP/TAZ信号通路对卵巢癌细胞增殖、凋亡和侵袭的影响[J].现代妇产科进展,2023,32(12):924-929.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,27(9):695-759.
[9] 吴文钰,李斐斐,CHUNG S L,等.中西医治疗乳腺癌术后他莫昔芬相关子宫内膜病变研究进展[J].陕西中医,2023,44(12):1831-1833.
[10] CORSO G,MAGNONI F.Hereditary breast cancer:Translation into clinical practice of recent american society of clinical oncology,american society of radiation oncology,and society of surgical oncology recommendations[J].Eur J Cancer Prev,2021,30(4):311-314.
[11] 何梅,赵振慧,李迅.乳腺癌规范化根治术后复发转移的多因素调查[J].河北医药,2021,43(11):1735-1738.
[12] 贾丽君,尹晓然,昝瑛.Nef对乳腺癌细胞survivin与RASSF2基因的调控及细胞凋亡[J].西部医学,2021,33(4):478-482.
[13] 宋天豹,秦铁城,张克钊,等.乳腺癌原发肿瘤组织HES1、Her2、CXCR4及Survivin的表达及与术后复发、生存的关系[J].中国煤炭工业医学杂志,2021,24(5):530-535.
[14] 王建君,徐小艳,冯智坤,等.乳腺浸润性导管癌中survivin与NF-κB的表达及其临床意义[J].中国普通外科杂志,2020,29(11):1327-1335.
[15] 陈鹏,徐婷,郭丹,等.YAP蛋白在HER2阳性乳腺癌拉帕替尼耐药中的作用[J].第三军医大学学报,2020,42(7):692-698.
[16] 祝景伟,佟经伟,许培权.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义[J].陕西医学杂志,2020,49(8):940-943.
[17] 冯晓云,李斌,贾小力,等.术前Yes相关蛋白表达与乳腺癌患者改良根治术后短期复发转移的相关性[J].中华实用诊断与治疗杂志,2021,35(8):771-774.
[18] 杜华强,安平,杜丽雯,等.甲状腺癌超声弹性成像定量参数与叉头盒A1、Yes相关蛋白的相关性研究[J].现代生物医学进展,2022,22(8):1484-1488.
[19] 蔚芳芳,赵琪,杨丽萍,等.乳腺癌患者血液学参数与HER-2表达的关系[J].检验医学,2022,37(6):514-517.
[20] 刘晓瑜,林翠君,黄洁,等.联合超声、MRI及钼靶评估HER-2过表达型及三阴性乳腺癌的诊断价值研究[J].临床放射学杂志,2023,42(7):1098-1102.
[21] 杨红,王洲,任永凤,等.超声特征与临床因素对HER2+浸润性乳腺癌的预测价值[J].陕西医学杂志,2023,52(8):1051-1054.
[22] 郑向欣,张旭旭,吴骥,等.吡咯替尼联合TCbH方案治疗首诊局部晚期HER-2阳性年轻乳腺癌患者的疗效及安全性[J].中国普通外科杂志,2021,30(11):1304-1310.
[23] 王亮,朱一平,吴小芳,等.GCDFP15和Calponin在宫颈病变组织中表达及临床预后意义[J].中华肿瘤防治杂志,2022,29(16):1194-1200.
[24] AHADI M,MORADI A,RABIEE E,et al.Evaluation of GATA3 and GCDFP15 expression in triple negative breast cancers[J].Iran J Pathol,2023,18(1):90-95.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(1):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(1):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(1):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(1):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(1):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(1):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[10]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(1):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]

备注/Memo

备注/Memo:
基金项目:河北省医学科学研究重点课题计划项目(20181495)
更新日期/Last Update: 2025-01-06